passing marks the end of a brilliant life dedicated to the prevention of disease through persistent research into the deleterious effects of hazardous occupational and environmental exposures.
Dr. Selikoff's career at Mount Sinai School of Medicine spanned 50 years, from the fledgling days of the Department of Pulmonary Medicine under the tutelage of Dr. Coleman Rabin, to the recognition of his work with Dr. E. H. Robitzek in the development of isoniazid therapy for tuberculosis, to his standard-setting prospective cohort studies of asbestos insulators, with Dr. E. Cuyler Hammond of the American Cancer Society. Now the task is to carry on Professor Selikoff's mission, to honor his legacy of hard work and courageous publication, and yet also to build upon that legacy to keep the field of occupational medicine strong, and to keep the American Journal of Industrial Medicine current and relevant into the next century.
To accomplish these ends, the Journal will continue in the years ahead to seek contributions in the following areas: clinical occupational medicine; surveillance; epidemiological studies, particularly those that combine evaluations of populations with biological markers of exposure, disease and susceptibility; and studies of preventive interventions in the workplace, particularly those that utilize objective indices of prevention.
Within the next two years, we plan to have special issues dealing in whole or in part with the following topics-the health hazards of child labor; new developments in occupational lead poisoning; and molecular markers of occupational cancer. We welcome suggestions for additional special topics.
We look forward to robust submissions, enhanced by rigorous reviews. Such works will continue the dissemination of information that long was Dr. Selikoff's hallmark.